1. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers 
Janine J.L Oberyé, Bernadette M.J.L Mannaerts, Jan A.M Huisman, Cees J Timmer 
Fertility and Sterility 
Volume 72, Issue 6, Pages (December 1999)
DOI: /S (99)

2. Figure 1
Log-linear plot of mean (±SD) serum ganirelix concentrations at steady state after multiple-dose SC administration of mg, 0.25 mg, and 0.50 mg of ganirelix (15 subjects per dose group).
Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999.
Fertility and Sterility  , DOI: ( /S (99) )

3. Figure 2
Median predose serum hormone concentrations during multiple-dose SC administration of mg (▵), 0.25 mg (•), and 0.50 mg (□) of ganirelix (15 subjects per dose group). (A), LH concentrations. (B), FSH concentrations. (C), E2 concentrations.
Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999.
Fertility and Sterility  , DOI: ( /S (99) )

4. Figure 3
Median serum hormone concentrations during one dosing interval and recovery after multiple-dose SC administration of mg (▵), 0.25 mg (•), and 0.50 mg (□) of ganirelix (15 subjects per dose group). (A), LH concentrations. (B), FSH concentrations. (C), E2 concentrations.
Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999.
Fertility and Sterility  , DOI: ( /S (99) )